个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an antiPDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Zhou, C.[1] ; Wang, Z.[2] ; Sun, Y.[3] ; Cao, L.[4] ; Ma, Z.[5] ; Wu, R.[6] ; Yu, Y.[7] ; Yao, W.[8] ; Chang, J.[9] ; Chen, J.[10] ; Zhuang, W.[11] ; Cui, J.[12] ; Chen, X.[13] ; Lu, Y.[14] ; Shen, H.[15] ; Li, P.[16] ; Wang, J.[16] ; Sun, B.[16] ; Lu, D.[16] ; Yang, J.[16] ;
机构： [1]Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, China [2]The Department of Respiratory Oncology, Beijing Cancer Hospital, Beijing, China [3]Oncology, Jinan Central Hospital, Jinan, China [4]Respiratory Medicine Department, Anhui Provincial Hospital, Hefei, China [5]Department Of Respiratory Medicine, Henan Cancer Hospital, Zhengzhou, China [6]Oncology Department, Shengjing Hospital of China Medical University, Hua Xiang Branch Hospital, Shenyang, China [7]Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China [8]Department of Thoracic Oncology, Sichuan Cancer Hospital & Institute, Chengdu, China [9]Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Institute of Thoracic Oncology, Fudan University, Shanghai, China [10]Oncology, Hunan Cancer Hospital, Changsha, China [11]Medical Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, China [12]Cancer Center, First Hospital of Jilin University, Changchun, China [13]Department of Oncology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China [14]Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China [15]Department of Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, China [16]Clinical Development and Regulatory Affairs, CStone Pharmaceuticals (Su Zhou) Co., Ltd, Suzhou, China
出处：
DOI： 10.1016/j.annonc.2020.10.368
ISSN：
基金：
CStone Pharmaceuticals
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2020]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者机构： [1]Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, China
推荐引用方式(GB/T 7714)：
Zhou C.,Wang Z.,Sun Y.,et al.GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an antiPDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)[J].ANNALS OF ONCOLOGY.2020,31:S1386-S1386.doi:10.1016/j.annonc.2020.10.368.
APA：
Zhou, C.,Wang, Z.,Sun, Y.,Cao, L.,Ma, Z....&Yang, J..(2020).GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an antiPDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC).ANNALS OF ONCOLOGY,31,
MLA：
Zhou, C.,et al."GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an antiPDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)".ANNALS OF ONCOLOGY 31.(2020):S1386-S1386

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号